Academy of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou 350122, China.
J Tradit Chin Med. 2013 Feb;33(1):34-8. doi: 10.1016/s0254-6272(13)60097-7.
To investigate the effect of Xiaoaiping Injection (XAP) on advanced hepatocellular carcinoma (HCC) in patients.
Sixty-eight patients with advanced HCC were assigned to a control group of 36 and a treatment group of 32. The control group was treated with best supportive treatment (BST) and the treatment group was given XAP plus BST. XAP was administered daily by i.v. and the treatment course was lasted for 30 days for both groups. The immediate therapeutic efficacy, Karnofsky performance status (KPS) scores, and the changes in immunity indicators (CD3+, CD4+ and CD8+ T cells) were measured and compared before and after treatment. The progression-free survival (PFS) rate and overall survival (OS) rate in the 2 groups were analyzed.
The immediate therapeutic efficacy and KPS of the treatment group were better than those in the control (P < 0.05). Patients in the treatment group had higher percentages of CD3 and CD4 T-lymphocytes in peripheral blood than those in the control group (P < 0.05). The median survival time was 27.0 weeks in the treatment group and 24.5 weeks in the control group. The 6-months cumulative survival rates in the treatment and control groups were 33.3% and 25.0%, respectively, with no significant difference (P > 0.05). The PFS was 18 weeks in the treatment group and 15 weeks in control group (P < 0.05).
XAP enhances the quality of life (QOL) of patients with advanced HCC, improves their immunity and extends their PFS.
观察消癌平注射液（XAP）治疗晚期肝癌的临床疗效。
将 68 例晚期肝癌患者分为对照组（36 例）和观察组（32 例）。对照组给予最佳支持治疗（BST），观察组给予 XAP 联合 BST。XAP 每日静脉滴注，两组疗程均为 30 天。比较两组患者治疗后的近期疗效、卡氏功能状态评分（KPS）和免疫指标（CD3+、CD4+、CD8+T 细胞）的变化，分析两组患者的无进展生存（PFS）率和总生存（OS）率。
观察组的近期疗效和 KPS 评分均优于对照组（P<0.05）。观察组患者外周血 CD3 和 CD4T 淋巴细胞比例高于对照组（P<0.05）。观察组中位生存时间为 27.0 周，对照组为 24.5 周。观察组和对照组的 6 个月累积生存率分别为 33.3%和 25.0%，差异无统计学意义（P>0.05）。观察组的 PFS 为 18 周，对照组为 15 周，观察组 PFS 长于对照组（P<0.05）。
XAP 可提高晚期肝癌患者的生活质量，改善免疫功能，延长患者的 PFS。
